Asset profile
sNN0029 infusion solution
Unknown / undisclosed
Evidence outlook · program status
Discontinued (2015-10), after a negative readout
sNN0029 was Newron Sweden's intracerebroventricular VEGF-A infusion solution for amyotrophic lateral sclerosis. All continuation studies were terminated in October 2015 after an interim review found no favourable benefit-risk ratio, compounded by infusion-system supply problems. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.